Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Chairman Rakesh Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • May 14
Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026 Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations. 공시 • Dec 16
Kromek Group plc to Report First Half, 2026 Results on Jan 20, 2026 Kromek Group plc announced that they will report first half, 2026 results on Jan 20, 2026 공시 • Oct 28
Kromek Group plc Provides earnings Guidance for the First Half of 2026 Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division. 공시 • Sep 17
Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026 Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations. 공시 • Jan 30
Kromek Group plc Provides Earnings Guidance for the Year 2025 Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits. 공시 • Nov 19
Kromek Group plc, Annual General Meeting, Dec 13, 2024 Kromek Group plc, Annual General Meeting, Dec 13, 2024. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham, ts21 3ff, sedgefield United Kingdom New Risk • Nov 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£7.8m). Currently unprofitable and not forecast to become profitable next year (UK£3.4m net loss next year). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Market cap is less than US$100m (€50.6m market cap, or US$54.2m). Buy Or Sell Opportunity • Oct 29
Now 24% overvalued Over the last 90 days, the stock has fallen 1.5% to €0.066. The fair value is estimated to be €0.053, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to decline by 3.2% in the next year. Reported Earnings • Oct 28
Full year 2024 earnings released: UK£0.006 loss per share (vs UK£0.014 loss in FY 2023) Full year 2024 results: UK£0.006 loss per share (improved from UK£0.014 loss in FY 2023). Revenue: UK£19.4m (up 12% from FY 2023). Net loss: UK£3.29m (loss narrowed 46% from FY 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. New Risk • Aug 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported October 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£4.6m net loss next year). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (€41.0m market cap, or US$45.2m). Board Change • Mar 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Wilks was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 
